Patients can now receive Tukysa in combination with trastuzumab and pertuzumab following their initial induction treatment. This decision marks a significant shift for the drug, which first entered the market in 2020 specifically for metastatic breast cancer, moving its application into an earlier stage of the disease cycle.
In section Market Quotes
FDA Broadens Approval for Pfizer Breast Cancer Drug Tukysa
A 36% reduction in the risk of disease progression or death has prompted the FDA to expand the use of Pfizer’s Tukysa. The regulatory green light allows the drug to be administered as a front-line maintenance therapy for adults battling unresectable locally advanced or metastatic HER2-positive breast cancer.
Clinical data from the Phase 3 trial supports this move, demonstrating improved outcomes for patients after their induction phase. While the safety profile remains largely consistent with previous findings, Pfizer noted an increase in the severity of hepatotoxicity. This form of drug-induced liver damage remains a primary clinical consideration for physicians prescribing the maintenance regimen.
Comments (0)
No comments yet. Be the first!